What's Happening?
PhaseWell Research, a multisite clinical research company based in Nashville, Tennessee, has announced a strategic partnership with the Latin Clinical Trial Center (LCTC) in San Juan, Puerto Rico. This collaboration aims to integrate LCTC into PhaseWell's
national network, thereby expanding clinical trial access and therapeutic reach across various medical fields, including cardiometabolic, cardiovascular, immunology, and infectious diseases. LCTC, founded in 2006 by Dr. Carlos A. Sariol, has a strong track record of conducting over 85 clinical studies and contributing to the approval of more than 10 therapeutic products. The partnership is expected to enhance PhaseWell's capabilities in Puerto Rico, providing more patients with access to clinical trials and advancing the development of new therapies.
Why It's Important?
This partnership is significant as it addresses the underrepresentation of Puerto Rico in clinical research, despite its potential in terms of talent and patient communities. By joining forces with LCTC, PhaseWell Research can leverage LCTC's established presence and patient trust in Puerto Rico to increase participation in clinical trials. This move not only benefits the local population by providing access to cutting-edge medical research but also strengthens PhaseWell's position in the clinical research industry. The collaboration is poised to enhance the development of therapies in high-demand therapeutic areas, potentially leading to more effective treatments and improved healthcare outcomes.
What's Next?
The partnership is expected to facilitate the expansion of PhaseWell's clinical trial network into Puerto Rico, increasing trial access for diverse and multicultural patient populations. As PhaseWell and LCTC work together, they will likely focus on integrating their operations and aligning their research goals to maximize the impact of their collaboration. This may involve launching new clinical trials, expanding existing ones, and exploring additional therapeutic areas. The success of this partnership could serve as a model for similar collaborations in other underrepresented regions, further advancing the field of clinical research.
